Spine Biologics Market Size by Product, Surgery Type, End-User, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2030

4.3%
CAGR (2024-2030)
2.71 USD Bn.
Market Size
316
Report Pages
148
Market Tables

Overview

The Spine Biologics Market size was valued at USD 2.71 Billion in 2023 and the total Spine Biologics revenue is expected to grow at a CAGR of 4.3% from 2024 to 2030, reaching nearly USD 3.65 Billion.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.

Spine biologics is a treatment that is used during spine fusion surgery for the treatment of spinal deformities that comprise spinal cord injuries, trauma, degenerative disc disease, and tumors. It stimulates the growth of the bone formation over different stages which include inflammatory, repair, and remodeling.Spine Biologics Market SnapshotTo know about the Research Methodology:-Request Free Sample Report

Major factors that are driving the spine biologics market growth include an increase in the number of geriatric population, benefits providing by spine biologics is faster recovery, minimal postoperative time, and ability to activate cellular growth. Spinal injuries can be because of the enlargement of bones & joints, thickening of the band of the tissue, which supports the spine. This is the key factor that is fuelling market growth in the upcoming years. People who are at the high risk of spinal deformities need to undergo spinal fusion surgery thus growing its demand in the global market. However, higher cost of the bone grafts, hostile reimbursement scenario, and concerns regarding the bone grafting procedures are expected to hinder the spine biologics market growth.

The report covers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a significant role in the enlargement of the market from 2024 to 2030.

Based on the product, the spinal allografts segment is expected to register a major XX% revenue share in the spine biologics market globally. The spinal allografts are an assumption of allografts over auto grafts is quickly increasing owing to properties such as immediate operational support and osteoconductivity. Moreover, allografts form not require another surgery to harvest the bone, and coiled healing. Hence, natural bone grafts are harvested from a patient’s body.

The hospital's segment is expected to dominate the xx% market share during the forecast period. The hospitals' segment is mainly determined by an improved number of spine fusion surgeries performed in these facilities. However, high hospitalization charges have converted into reducing patient admittances in hospitals, with the number of outpatient visits observing a surge. This is likely to threaten the implementation of spine biologics in hospital surroundings over the forecast period.

Region-wise, The Asia Pacific market is projected to demonstrate significant growth owing to the presence of a large patient pool and developing awareness among surgeons and patients pertinent to the benefits of biologics. Improvements in infrastructure and healthcare facilities in the region and the high prevalence of spine injuries are some of the factors dynamic the regional market. Changing lifestyle designs have resulted in an increasing prevalence of obesity, which is also likely to fuel the market over the forecast period.

The report covers the recent development in the spine biologics market like, in March 2021, Cell Right Technologies Signed a Multi-Year Distribution Agreement By Arthrex Inc, a producer of orthopedic surgical solutions. Cell right is an establishment that creations osteobiologics which are used in orthopedic, spine and intensifying the healing ventures of problems caused by pain & disease. The multi-time commitment would provide surgeons arrival to qualified osteobiologics and advanced surgical instrumentation and techniques helping to succeed better patient effects.

The objective of the report is to present a complete calculation of the Global Spine Biologics Market and contains thoughtful insights, historical data, facts, industry-validated market data and plans with a suitable set of assumptions and methodology. The report also helps in the Global Spine Biologics Market is a dynamic structure by identifying and analyzing the market segments and project the global market size. The additional, report also focuses on the competitive analysis of key player’s by-product, financial position, price, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Global Spine Biologics Market.

 Spine Biologics Market Scope: Inquire before buying

Spine Biologics Market
Report Coverage Details
Base Year: 2023 Forecast Period: 2024-2030
Historical Data: 2018 to 2023 Market Size in 2023: USD 2.71 Bn.
Forecast Period 2024 to 2030 CAGR: 4.3% Market Size in 2030: USD 3.65 Bn.
Segments Covered: by Product Bone Allografts
Machined bone allograft
Demineralized bone matrix
Bone Graft Substitute
Synthetic Bone Grafts
Demineralized Bone Matrix (DBM)
Bone Morphogenetic Proteins (BMP)
Spinal Allografts
Machined Bones Allograft
Demineralized Bone Matrix
Platelet Rich Plasma
Cell-based Matrix
by Surgery Type Anterior Cervical Discectomy and Fusion (ACDF)
Transforamenal Lumbar Interbody Fusion (TLIF)
Anterior Lumbar Interbody Fusion (ALIF)
Lateral Lumbar Interbody Fusion (LLIF)
Others
by End-User Hospitals
Ambulatory Surgical Centers
Others

Spine Biologics Market By Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

 Spine Biologics Market Key Players

1. Medtronic Inc.
2. DePuy Synthes Companies
3. Zimmer Holding Inc.
4. Nuvasive Inc
5. Stryker Corporation
6. Orthofix International N.V.
7. Exactech Inc.
8. Wright Medical Technology
9. Alphatec Holdings
10.SeaSpine
11.Globus Medical
12.RTI Surgical

Frequently Asked Questions:

1. Which region has the largest share in Global Spine Biologics Market?
Ans: Asia Pacific region held the highest share in 2023.

2. What is the growth rate of Global Spine Biologics Market?
Ans: The Global Spine Biologics Market is growing at a CAGR of 4.3% during forecasting period 2024-2030.

3. What is scope of the Global Spine Biologics market report?
Ans: Global Spine Biologics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Spine Biologics market?
Ans: The important key players in the Global Spine Biologics Market are – Medtronic Inc., DePuy Synthes Companies, Zimmer Holding Inc., Nuvasive Inc, Stryker Corporation, Orthofix International N.V., Exactech Inc., Wright Medical Technology, Alphatec Holdings, SeaSpine, Globus Medical, and RTI Surgical.

5. What was the Global Spine Biologics Market size in 2023?
Ans: The Global Spine Biologics Market size was USD 2.71 Billion in 2023.

Table of Contents

Spine Biologics Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Spine Biologics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Spine Biologics Market Analysis and Forecast 6.1. Spine Biologics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Spine Biologics Market Analysis and Forecast, by Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. Spine Biologics Market Value Share Analysis, by Product 7.4. Spine Biologics Market Size (US$ Bn) Forecast, by Product 7.5. Spine Biologics Market Analysis, by Product 7.6. Spine Biologics Market Attractiveness Analysis, by Product 8. Spine Biologics Market Analysis and Forecast, by Surgery Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Spine Biologics Market Value Share Analysis, by Surgery Type 8.4. Spine Biologics Market Size (US$ Bn) Forecast, by Surgery Type 8.5. Spine Biologics Market Analysis, by Surgery Type 8.6. Spine Biologics Market Attractiveness Analysis, by Surgery Type 9. Spine Biologics Market Analysis and Forecast, by End-User 9.1. Introduction and Definition 9.2. Key Findings 9.3. Spine Biologics Market Value Share Analysis, by End-User 9.4. Spine Biologics Market Size (US$ Bn) Forecast, by End-User 9.5. Spine Biologics Market Analysis, by End-User 9.6. Spine Biologics Market Attractiveness Analysis, by End-User 10. Spine Biologics Market Analysis, by Region 10.1. Spine Biologics Market Value Share Analysis, by Region 10.2. Spine Biologics Market Size (US$ Bn) Forecast, by Region 10.3. Spine Biologics Market Attractiveness Analysis, by Region 11. North America Spine Biologics Market Analysis 11.1. Key Findings 11.2. North America Spine Biologics Market Overview 11.3. North America Spine Biologics Market Value Share Analysis, by Product 11.4. North America Spine Biologics Market Forecast, by Product 11.4.1. Bone Allografts 11.4.1.1. Machined bone allograft 11.4.1.2. Demineralized bone matrix 11.4.2. Bone Graft Substitute 11.4.2.1. Synthetic Bone Grafts 11.4.2.2. Demineralized Bone Matrix (DBM) 11.4.2.3. Bone Morphogenetic Proteins (BMP) 11.4.3. Spinal Allografts 11.4.3.1. Machined Bones Allograft 11.4.3.2. Demineralized Bone Matrix 11.4.4. Platelet Rich Plasma 11.4.5. Cell-based Matrix 11.5. North America Spine Biologics Market Value Share Analysis, by Surgery Type 11.6. North America Spine Biologics Market Forecast, by Surgery Type 11.6.1. Anterior Cervical Discectomy and Fusion (ACDF) 11.6.2. Transforamenal Lumbar Interbody Fusion (TLIF) 11.6.3. Anterior Lumbar Interbody Fusion (ALIF) 11.6.4. Lateral Lumbar Interbody Fusion (LLIF) 11.6.5. Others 11.7. North America Spine Biologics Market Value Share Analysis, by End-User 11.8. North America Spine Biologics Market Forecast, by End-User 11.8.1. Hospitals 11.8.2. Ambulatory Surgical Centers 11.8.3. Others 11.9. North America Spine Biologics Market Value Share Analysis, by Country 11.10. North America Spine Biologics Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Spine Biologics Market Analysis, by Country 11.12. U.S. Spine Biologics Market Forecast, by Product 11.12.1. Bone Allografts 11.12.1.1. Machined bone allograft 11.12.1.2. Demineralized bone matrix 11.12.2. Bone Graft Substitute 11.12.2.1. Synthetic Bone Grafts 11.12.2.2. Demineralized Bone Matrix (DBM) 11.12.2.3. Bone Morphogenetic Proteins (BMP) 11.12.3. Spinal Allografts 11.12.3.1. Machined Bones Allograft 11.12.3.2. Demineralized Bone Matrix 11.12.4. Platelet Rich Plasma 11.12.5. Cell-based Matrix 11.13. U.S. Spine Biologics Market Forecast, by Surgery Type 11.13.1. Anterior Cervical Discectomy and Fusion (ACDF) 11.13.2. Transforamenal Lumbar Interbody Fusion (TLIF) 11.13.3. Anterior Lumbar Interbody Fusion (ALIF) 11.13.4. Lateral Lumbar Interbody Fusion (LLIF) 11.13.5. Others 11.14. U.S. Spine Biologics Market Forecast, by End-User 11.14.1. Hospitals 11.14.2. Ambulatory Surgical Centers 11.14.3. Others 11.15. Canada Spine Biologics Market Forecast, by Product 11.15.1. Bone Allografts 11.15.1.1. Machined bone allograft 11.15.1.2. Demineralized bone matrix 11.15.2. Bone Graft Substitute 11.15.2.1. Synthetic Bone Grafts 11.15.2.2. Demineralized Bone Matrix (DBM) 11.15.2.3. Bone Morphogenetic Proteins (BMP) 11.15.3. Spinal Allografts 11.15.3.1. Machined Bones Allograft 11.15.3.2. Demineralized Bone Matrix 11.15.4. Platelet Rich Plasma 11.15.5. Cell-based Matrix 11.16. Steel Canada Spine Biologics Market Forecast, by Surgery Type 11.16.1. Anterior Cervical Discectomy and Fusion (ACDF) 11.16.2. Transforamenal Lumbar Interbody Fusion (TLIF) 11.16.3. Anterior Lumbar Interbody Fusion (ALIF) 11.16.4. Lateral Lumbar Interbody Fusion (LLIF) 11.16.5. Others 11.17. Canada Spine Biologics Market Forecast, by End-User 11.17.1. Hospitals 11.17.2. Ambulatory Surgical Centers 11.17.3. Others 11.18. North America Spine Biologics Market Attractiveness Analysis 11.18.1. By Product 11.18.2. By Surgery Type 11.18.3. By End-User 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Spine Biologics Market Analysis 12.1. Key Findings 12.2. Europe Spine Biologics Market Overview 12.3. Europe Spine Biologics Market Value Share Analysis, by Product 12.4. Europe Spine Biologics Market Forecast, by Product 12.4.1. Bone Allografts 12.4.1.1. Machined bone allograft 12.4.1.2. Demineralized bone matrix 12.4.2. Bone Graft Substitute 12.4.2.1. Synthetic Bone Grafts 12.4.2.2. Demineralized Bone Matrix (DBM) 12.4.2.3. Bone Morphogenetic Proteins (BMP) 12.4.3. Spinal Allografts 12.4.3.1. Machined Bones Allograft 12.4.3.2. Demineralized Bone Matrix 12.4.4. Platelet Rich Plasma 12.4.5. Cell-based Matrix 12.5. Europe Spine Biologics Market Value Share Analysis, by Surgery Type 12.6. Europe Spine Biologics Market Forecast, by Surgery Type 12.6.1. Anterior Cervical Discectomy and Fusion (ACDF) 12.6.2. Transforamenal Lumbar Interbody Fusion (TLIF) 12.6.3. Anterior Lumbar Interbody Fusion (ALIF) 12.6.4. Lateral Lumbar Interbody Fusion (LLIF) 12.6.5. Others 12.7. Europe Spine Biologics Market Value Share Analysis, by End-User 12.8. Europe Spine Biologics Market Forecast, by End-User 12.8.1. Hospitals 12.8.2. Ambulatory Surgical Centers 12.8.3. Others 12.9. Europe Spine Biologics Market Value Share Analysis, by Country 12.10. Europe Spine Biologics Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Spine Biologics Market Analysis, by Country 12.12. Germany Spine Biologics Market Forecast, by Product 12.12.1. Bone Allografts 12.12.1.1. Machined bone allograft 12.12.1.2. Demineralized bone matrix 12.12.2. Bone Graft Substitute 12.12.2.1. Synthetic Bone Grafts 12.12.2.2. Demineralized Bone Matrix (DBM) 12.12.2.3. Bone Morphogenetic Proteins (BMP) 12.12.3. Spinal Allografts 12.12.3.1. Machined Bones Allograft 12.12.3.2. Demineralized Bone Matrix 12.12.4. Platelet Rich Plasma 12.12.5. Cell-based Matrix 12.13. Germany Spine Biologics Market Forecast, by Surgery Type 12.13.1. Anterior Cervical Discectomy and Fusion (ACDF) 12.13.2. Transforamenal Lumbar Interbody Fusion (TLIF) 12.13.3. Anterior Lumbar Interbody Fusion (ALIF) 12.13.4. Lateral Lumbar Interbody Fusion (LLIF) 12.13.5. Others 12.14. Germany Spine Biologics Market Forecast, by End-User 12.14.1. Hospitals 12.14.2. Ambulatory Surgical Centers 12.14.3. Others 12.15. U.K. Spine Biologics Market Forecast, by Product 12.15.1. Bone Allografts 12.15.1.1. Machined bone allograft 12.15.1.2. Demineralized bone matrix 12.15.2. Bone Graft Substitute 12.15.2.1. Synthetic Bone Grafts 12.15.2.2. Demineralized Bone Matrix (DBM) 12.15.2.3. Bone Morphogenetic Proteins (BMP) 12.15.3. Spinal Allografts 12.15.3.1. Machined Bones Allograft 12.15.3.2. Demineralized Bone Matrix 12.15.4. Platelet Rich Plasma 12.15.5. Cell-based Matrix 12.16. U.K. Spine Biologics Market Forecast, by Surgery Type 12.16.1. Anterior Cervical Discectomy and Fusion (ACDF) 12.16.2. Transforamenal Lumbar Interbody Fusion (TLIF) 12.16.3. Anterior Lumbar Interbody Fusion (ALIF) 12.16.4. Lateral Lumbar Interbody Fusion (LLIF) 12.16.5. Others 12.17. U.K. Spine Biologics Market Forecast, by End-User 12.17.1. Hospitals 12.17.2. Ambulatory Surgical Centers 12.17.3. Others 12.18. France Spine Biologics Market Forecast, by Product 12.18.1. Bone Allografts 12.18.1.1. Machined bone allograft 12.18.1.2. Demineralized bone matrix 12.18.2. Bone Graft Substitute 12.18.2.1. Synthetic Bone Grafts 12.18.2.2. Demineralized Bone Matrix (DBM) 12.18.2.3. Bone Morphogenetic Proteins (BMP) 12.18.3. Spinal Allografts 12.18.3.1. Machined Bones Allograft 12.18.3.2. Demineralized Bone Matrix 12.18.4. Platelet Rich Plasma 12.18.5. Cell-based Matrix 12.19. France Spine Biologics Market Forecast, by Surgery Type 12.19.1. Anterior Cervical Discectomy and Fusion (ACDF) 12.19.2. Transforamenal Lumbar Interbody Fusion (TLIF) 12.19.3. Anterior Lumbar Interbody Fusion (ALIF) 12.19.4. Lateral Lumbar Interbody Fusion (LLIF) 12.19.5. Others 12.20. France Spine Biologics Market Forecast, by End-User 12.20.1. Hospitals 12.20.2. Ambulatory Surgical Centers 12.20.3. Others 12.21. Italy Spine Biologics Market Forecast, by Product 12.21.1. Bone Allografts 12.21.1.1. Machined bone allograft 12.21.1.2. Demineralized bone matrix 12.21.2. Bone Graft Substitute 12.21.2.1. Synthetic Bone Grafts 12.21.2.2. Demineralized Bone Matrix (DBM) 12.21.2.3. Bone Morphogenetic Proteins (BMP) 12.21.3. Spinal Allografts 12.21.3.1. Machined Bones Allograft 12.21.3.2. Demineralized Bone Matrix 12.21.4. Platelet Rich Plasma 12.21.5. Cell-based Matrix 12.22. Italy Spine Biologics Market Forecast, by Surgery Type 12.22.1. Anterior Cervical Discectomy and Fusion (ACDF) 12.22.2. Transforamenal Lumbar Interbody Fusion (TLIF) 12.22.3. Anterior Lumbar Interbody Fusion (ALIF) 12.22.4. Lateral Lumbar Interbody Fusion (LLIF) 12.22.5. Others 12.23. Italy Spine Biologics Market Forecast, by End-User 12.23.1. Hospitals 12.23.2. Ambulatory Surgical Centers 12.23.3. Others 12.24. Spain Spine Biologics Market Forecast, by Product 12.24.1. Bone Allografts 12.24.1.1. Machined bone allograft 12.24.1.2. Demineralized bone matrix 12.24.2. Bone Graft Substitute 12.24.2.1. Synthetic Bone Grafts 12.24.2.2. Demineralized Bone Matrix (DBM) 12.24.2.3. Bone Morphogenetic Proteins (BMP) 12.24.3. Spinal Allografts 12.24.3.1. Machined Bones Allograft 12.24.3.2. Demineralized Bone Matrix 12.24.4. Platelet Rich Plasma 12.24.5. Cell-based Matrix 12.25. Spain Spine Biologics Market Forecast, by Surgery Type 12.25.1. Anterior Cervical Discectomy and Fusion (ACDF) 12.25.2. Transforamenal Lumbar Interbody Fusion (TLIF) 12.25.3. Anterior Lumbar Interbody Fusion (ALIF) 12.25.4. Lateral Lumbar Interbody Fusion (LLIF) 12.25.5. Others 12.26. Spain Spine Biologics Market Forecast, by End-User 12.26.1. Hospitals 12.26.2. Ambulatory Surgical Centers 12.26.3. Others 12.27. Rest of Europe Spine Biologics Market Forecast, by Product 12.27.1. Bone Allografts 12.27.1.1. Machined bone allograft 12.27.1.2. Demineralized bone matrix 12.27.2. Bone Graft Substitute 12.27.2.1. Synthetic Bone Grafts 12.27.2.2. Demineralized Bone Matrix (DBM) 12.27.2.3. Bone Morphogenetic Proteins (BMP) 12.27.3. Spinal Allografts 12.27.3.1. Machined Bones Allograft 12.27.3.2. Demineralized Bone Matrix 12.27.4. Platelet Rich Plasma 12.27.5. Cell-based Matrix 12.28. Rest of Europe Spine Biologics Market Forecast, by Surgery Type 12.28.1. Anterior Cervical Discectomy and Fusion (ACDF) 12.28.2. Transforamenal Lumbar Interbody Fusion (TLIF) 12.28.3. Anterior Lumbar Interbody Fusion (ALIF) 12.28.4. Lateral Lumbar Interbody Fusion (LLIF) 12.28.5. Others 12.29. Rest Of Europe Spine Biologics Market Forecast, by End-User 12.29.1. Hospitals 12.29.2. Ambulatory Surgical Centers 12.29.3. Others 12.30. Europe Spine Biologics Market Attractiveness Analysis 12.30.1. By Product 12.30.2. By Surgery Type 12.30.3. By End-User 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Spine Biologics Market Analysis 13.1. Key Findings 13.2. Asia Pacific Spine Biologics Market Overview 13.3. Asia Pacific Spine Biologics Market Value Share Analysis, by Product 13.4. Asia Pacific Spine Biologics Market Forecast, by Product 13.4.1. Bone Allografts 13.4.1.1. Machined bone allograft 13.4.1.2. Demineralized bone matrix 13.4.2. Bone Graft Substitute 13.4.2.1. Synthetic Bone Grafts 13.4.2.2. Demineralized Bone Matrix (DBM) 13.4.2.3. Bone Morphogenetic Proteins (BMP) 13.4.3. Spinal Allografts 13.4.3.1. Machined Bones Allograft 13.4.3.2. Demineralized Bone Matrix 13.4.4. Platelet Rich Plasma 13.4.5. Cell-based Matrix 13.5. Asia Pacific Spine Biologics Market Value Share Analysis, by Surgery Type 13.6. Asia Pacific Spine Biologics Market Forecast, by Surgery Type 13.6.1. Anterior Cervical Discectomy and Fusion (ACDF) 13.6.2. Transforamenal Lumbar Interbody Fusion (TLIF) 13.6.3. Anterior Lumbar Interbody Fusion (ALIF) 13.6.4. Lateral Lumbar Interbody Fusion (LLIF) 13.6.5. Others 13.7. Asia Pacific Spine Biologics Market Value Share Analysis, by End-User 13.8. Asia Pacific Spine Biologics Market Forecast, by End-User 13.8.1. Hospitals 13.8.2. Ambulatory Surgical Centers 13.8.3. Others 13.9. Asia Pacific Spine Biologics Market Value Share Analysis, by Country 13.10. Asia Pacific Spine Biologics Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Spine Biologics Market Analysis, by Country 13.12. China Spine Biologics Market Forecast, by Product 13.12.1. Bone Allografts 13.12.1.1. Machined bone allograft 13.12.1.2. Demineralized bone matrix 13.12.2. Bone Graft Substitute 13.12.2.1. Synthetic Bone Grafts 13.12.2.2. Demineralized Bone Matrix (DBM) 13.12.2.3. Bone Morphogenetic Proteins (BMP) 13.12.3. Spinal Allografts 13.12.3.1. Machined Bones Allograft 13.12.3.2. Demineralized Bone Matrix 13.12.4. Platelet Rich Plasma 13.12.5. Cell-based Matrix 13.13. China Spine Biologics Market Forecast, by Surgery Type 13.13.1. Anterior Cervical Discectomy and Fusion (ACDF) 13.13.2. Transforamenal Lumbar Interbody Fusion (TLIF) 13.13.3. Anterior Lumbar Interbody Fusion (ALIF) 13.13.4. Lateral Lumbar Interbody Fusion (LLIF) 13.13.5. Others 13.14. China Spine Biologics Market Forecast, by End-User 13.14.1. Hospitals 13.14.2. Ambulatory Surgical Centers 13.14.3. Others 13.15. India Spine Biologics Market Forecast, by Product 13.15.1. Bone Allografts 13.15.1.1. Machined bone allograft 13.15.1.2. Demineralized bone matrix 13.15.2. Bone Graft Substitute 13.15.2.1. Synthetic Bone Grafts 13.15.2.2. Demineralized Bone Matrix (DBM) 13.15.2.3. Bone Morphogenetic Proteins (BMP) 13.15.3. Spinal Allografts 13.15.3.1. Machined Bones Allograft 13.15.3.2. Demineralized Bone Matrix 13.15.4. Platelet Rich Plasma 13.15.5. Cell-based Matrix 13.16. India Spine Biologics Market Forecast, by Surgery Type 13.16.1. Anterior Cervical Discectomy and Fusion (ACDF) 13.16.2. Transforamenal Lumbar Interbody Fusion (TLIF) 13.16.3. Anterior Lumbar Interbody Fusion (ALIF) 13.16.4. Lateral Lumbar Interbody Fusion (LLIF) 13.16.5. Others 13.17. India Spine Biologics Market Forecast, by End-User 13.17.1. Hospitals 13.17.2. Ambulatory Surgical Centers 13.17.3. Others 13.18. Japan Spine Biologics Market Forecast, by Product 13.18.1. Bone Allografts 13.18.1.1. Machined bone allograft 13.18.1.2. Demineralized bone matrix 13.18.2. Bone Graft Substitute 13.18.2.1. Synthetic Bone Grafts 13.18.2.2. Demineralized Bone Matrix (DBM) 13.18.2.3. Bone Morphogenetic Proteins (BMP) 13.18.3. Spinal Allografts 13.18.3.1. Machined Bones Allograft 13.18.3.2. Demineralized Bone Matrix 13.18.4. Platelet Rich Plasma 13.18.5. Cell-based Matrix 13.19. Japan Spine Biologics Market Forecast, by Surgery Type 13.19.1. Anterior Cervical Discectomy and Fusion (ACDF) 13.19.2. Transforamenal Lumbar Interbody Fusion (TLIF) 13.19.3. Anterior Lumbar Interbody Fusion (ALIF) 13.19.4. Lateral Lumbar Interbody Fusion (LLIF) 13.19.5. Others 13.20. Japan Spine Biologics Market Forecast, by End-User 13.20.1. Hospitals 13.20.2. Ambulatory Surgical Centers 13.20.3. Others 13.21. ASEAN Spine Biologics Market Forecast, by Product 13.21.1. Bone Allografts 13.21.1.1. Machined bone allograft 13.21.1.2. Demineralized bone matrix 13.21.2. Bone Graft Substitute 13.21.2.1. Synthetic Bone Grafts 13.21.2.2. Demineralized Bone Matrix (DBM) 13.21.2.3. Bone Morphogenetic Proteins (BMP) 13.21.3. Spinal Allografts 13.21.3.1. Machined Bones Allograft 13.21.3.2. Demineralized Bone Matrix 13.21.4. Platelet Rich Plasma 13.21.5. Cell-based Matrix 13.22. ASEAN Spine Biologics Market Forecast, by Surgery Type 13.22.1. Anterior Cervical Discectomy and Fusion (ACDF) 13.22.2. Transforamenal Lumbar Interbody Fusion (TLIF) 13.22.3. Anterior Lumbar Interbody Fusion (ALIF) 13.22.4. Lateral Lumbar Interbody Fusion (LLIF) 13.22.5. Others 13.23. ASEAN Spine Biologics Market Forecast, by End-User 13.23.1. Hospitals 13.23.2. Ambulatory Surgical Centers 13.23.3. Others 13.24. Rest of Asia Pacific Spine Biologics Market Forecast, by Product 13.24.1. Bone Allografts 13.24.1.1. Machined bone allograft 13.24.1.2. Demineralized bone matrix 13.24.2. Bone Graft Substitute 13.24.2.1. Synthetic Bone Grafts 13.24.2.2. Demineralized Bone Matrix (DBM) 13.24.2.3. Bone Morphogenetic Proteins (BMP) 13.24.3. Spinal Allografts 13.24.3.1. Machined Bones Allograft 13.24.3.2. Demineralized Bone Matrix 13.24.4. Platelet Rich Plasma 13.24.5. Cell-based Matrix 13.25. Rest of Asia Pacific Spine Biologics Market Forecast, by Surgery Type 13.25.1. Anterior Cervical Discectomy and Fusion (ACDF) 13.25.2. Transforamenal Lumbar Interbody Fusion (TLIF) 13.25.3. Anterior Lumbar Interbody Fusion (ALIF) 13.25.4. Lateral Lumbar Interbody Fusion (LLIF) 13.25.5. Others 13.26. Rest of Asia Pacific Spine Biologics Market Forecast, by End-User 13.26.1. Hospitals 13.26.2. Ambulatory Surgical Centers 13.26.3. Others 13.27. Asia Pacific Spine Biologics Market Attractiveness Analysis 13.27.1. By Product 13.27.2. By Surgery Type 13.27.3. By End-User 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Spine Biologics Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Spine Biologics Market Overview 14.3. Middle East & Africa Spine Biologics Market Value Share Analysis, by Product 14.4. Middle East & Africa Spine Biologics Market Forecast, by Product 14.4.1. Bone Allografts 14.4.1.1. Machined bone allograft 14.4.1.2. Demineralized bone matrix 14.4.2. Bone Graft Substitute 14.4.2.1. Synthetic Bone Grafts 14.4.2.2. Demineralized Bone Matrix (DBM) 14.4.2.3. Bone Morphogenetic Proteins (BMP) 14.4.3. Spinal Allografts 14.4.3.1. Machined Bones Allograft 14.4.3.2. Demineralized Bone Matrix 14.4.4. Platelet Rich Plasma 14.4.5. Cell-based Matrix 14.5. Middle East & Africa Spine Biologics Market Value Share Analysis, by Surgery Type 14.6. Middle East & Africa Spine Biologics Market Forecast, by Surgery Type 14.6.1. Anterior Cervical Discectomy and Fusion (ACDF) 14.6.2. Transforamenal Lumbar Interbody Fusion (TLIF) 14.6.3. Anterior Lumbar Interbody Fusion (ALIF) 14.6.4. Lateral Lumbar Interbody Fusion (LLIF) 14.6.5. Others 14.7. Middle East & Africa Spine Biologics Market Value Share Analysis, by End-User 14.8. Middle East & Africa Spine Biologics Market Forecast, by End-User 14.8.1. Hospitals 14.8.2. Ambulatory Surgical Centers 14.8.3. Others 14.9. Middle East & Africa Spine Biologics Market Value Share Analysis, by Country 14.10. Middle East & Africa Spine Biologics Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Spine Biologics Market Analysis, by Country 14.12. GCC Spine Biologics Market Forecast, by Product 14.12.1. Bone Allografts 14.12.1.1. Machined bone allograft 14.12.1.2. Demineralized bone matrix 14.12.2. Bone Graft Substitute 14.12.2.1. Synthetic Bone Grafts 14.12.2.2. Demineralized Bone Matrix (DBM) 14.12.2.3. Bone Morphogenetic Proteins (BMP) 14.12.3. Spinal Allografts 14.12.3.1. Machined Bones Allograft 14.12.3.2. Demineralized Bone Matrix 14.12.4. Platelet Rich Plasma 14.12.5. Cell-based Matrix 14.13. GCC Spine Biologics Market Forecast, by Surgery Type 14.13.1. Anterior Cervical Discectomy and Fusion (ACDF) 14.13.2. Transforamenal Lumbar Interbody Fusion (TLIF) 14.13.3. Anterior Lumbar Interbody Fusion (ALIF) 14.13.4. Lateral Lumbar Interbody Fusion (LLIF) 14.13.5. Others 14.14. GCC Spine Biologics Market Forecast, by End-User 14.14.1. Hospitals 14.14.2. Ambulatory Surgical Centers 14.14.3. Others 14.15. South Africa Spine Biologics Market Forecast, by Product 14.15.1. Bone Allografts 14.15.1.1. Machined bone allograft 14.15.1.2. Demineralized bone matrix 14.15.2. Bone Graft Substitute 14.15.2.1. Synthetic Bone Grafts 14.15.2.2. Demineralized Bone Matrix (DBM) 14.15.2.3. Bone Morphogenetic Proteins (BMP) 14.15.3. Spinal Allografts 14.15.3.1. Machined Bones Allograft 14.15.3.2. Demineralized Bone Matrix 14.15.4. Platelet Rich Plasma 14.15.5. Cell-based Matrix 14.16. South Africa Spine Biologics Market Forecast, by Surgery Type 14.16.1. Anterior Cervical Discectomy and Fusion (ACDF) 14.16.2. Transforamenal Lumbar Interbody Fusion (TLIF) 14.16.3. Anterior Lumbar Interbody Fusion (ALIF) 14.16.4. Lateral Lumbar Interbody Fusion (LLIF) 14.16.5. Others 14.17. South Africa Spine Biologics Market Forecast, by End-User 14.17.1. Hospitals 14.17.2. Ambulatory Surgical Centers 14.17.3. Others 14.18. Rest of Middle East & Africa Spine Biologics Market Forecast, by Product 14.18.1. Bone Allografts 14.18.1.1. Machined bone allograft 14.18.1.2. Demineralized bone matrix 14.18.2. Bone Graft Substitute 14.18.2.1. Synthetic Bone Grafts 14.18.2.2. Demineralized Bone Matrix (DBM) 14.18.2.3. Bone Morphogenetic Proteins (BMP) 14.18.3. Spinal Allografts 14.18.3.1. Machined Bones Allograft 14.18.3.2. Demineralized Bone Matrix 14.18.4. Platelet Rich Plasma 14.18.5. Cell-based Matrix 14.19. Rest of Middle East & Africa Spine Biologics Market Forecast, by Surgery Type 14.19.1. Anterior Cervical Discectomy and Fusion (ACDF) 14.19.2. Transforamenal Lumbar Interbody Fusion (TLIF) 14.19.3. Anterior Lumbar Interbody Fusion (ALIF) 14.19.4. Lateral Lumbar Interbody Fusion (LLIF) 14.19.5. Others 14.20. Rest of Middle East & Africa Spine Biologics Market Forecast, by End-User 14.20.1. Hospitals 14.20.2. Ambulatory Surgical Centers 14.20.3. Others 14.21. Middle East & Africa Spine Biologics Market Attractiveness Analysis 14.21.1. By Product 14.21.2. By Surgery Type 14.21.3. By End-User 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Spine Biologics Market Analysis 15.1. Key Findings 15.2. South America Spine Biologics Market Overview 15.3. South America Spine Biologics Market Value Share Analysis, by Product 15.4. South America Spine Biologics Market Forecast, by Product 15.4.1. Bone Allografts 15.4.1.1. Machined bone allograft 15.4.1.2. Demineralized bone matrix 15.4.2. Bone Graft Substitute 15.4.2.1. Synthetic Bone Grafts 15.4.2.2. Demineralized Bone Matrix (DBM) 15.4.2.3. Bone Morphogenetic Proteins (BMP) 15.4.3. Spinal Allografts 15.4.3.1. Machined Bones Allograft 15.4.3.2. Demineralized Bone Matrix 15.4.4. Platelet Rich Plasma 15.4.5. Cell-based Matrix 15.5. South America Spine Biologics Market Value Share Analysis, by Surgery Type 15.6. South America Spine Biologics Market Forecast, by Surgery Type 15.6.1. Anterior Cervical Discectomy and Fusion (ACDF) 15.6.2. Transforamenal Lumbar Interbody Fusion (TLIF) 15.6.3. Anterior Lumbar Interbody Fusion (ALIF) 15.6.4. Lateral Lumbar Interbody Fusion (LLIF) 15.6.5. Others 15.7. South America Spine Biologics Market Value Share Analysis, by End-User 15.8. South America Spine Biologics Market Forecast, by End-User 15.8.1. Hospitals 15.8.2. Ambulatory Surgical Centers 15.8.3. Others 15.9. South America Spine Biologics Market Value Share Analysis, by Country 15.10. South America Spine Biologics Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Spine Biologics Market Analysis, by Country 15.12. Brazil Spine Biologics Market Forecast, by Product 15.12.1. Bone Allografts 15.12.1.1. Machined bone allograft 15.12.1.2. Demineralized bone matrix 15.12.2. Bone Graft Substitute 15.12.2.1. Synthetic Bone Grafts 15.12.2.2. Demineralized Bone Matrix (DBM) 15.12.2.3. Bone Morphogenetic Proteins (BMP) 15.12.3. Spinal Allografts 15.12.3.1. Machined Bones Allograft 15.12.3.2. Demineralized Bone Matrix 15.12.4. Platelet Rich Plasma 15.12.5. Cell-based Matrix 15.13. Brazil Spine Biologics Market Forecast, by Surgery Type 15.13.1. Anterior Cervical Discectomy and Fusion (ACDF) 15.13.2. Transforamenal Lumbar Interbody Fusion (TLIF) 15.13.3. Anterior Lumbar Interbody Fusion (ALIF) 15.13.4. Lateral Lumbar Interbody Fusion (LLIF) 15.13.5. Others 15.14. Brazil Spine Biologics Market Forecast, by End-User 15.14.1. Hospitals 15.14.2. Ambulatory Surgical Centers 15.14.3. Others 15.15. Mexico Spine Biologics Market Forecast, by Product 15.15.1. Bone Allografts 15.15.1.1. Machined bone allograft 15.15.1.2. Demineralized bone matrix 15.15.2. Bone Graft Substitute 15.15.2.1. Synthetic Bone Grafts 15.15.2.2. Demineralized Bone Matrix (DBM) 15.15.2.3. Bone Morphogenetic Proteins (BMP) 15.15.3. Spinal Allografts 15.15.3.1. Machined Bones Allograft 15.15.3.2. Demineralized Bone Matrix 15.15.4. Platelet Rich Plasma 15.15.5. Cell-based Matrix 15.16. Mexico Spine Biologics Market Forecast, by Surgery Type 15.16.1. Anterior Cervical Discectomy and Fusion (ACDF) 15.16.2. Transforamenal Lumbar Interbody Fusion (TLIF) 15.16.3. Anterior Lumbar Interbody Fusion (ALIF) 15.16.4. Lateral Lumbar Interbody Fusion (LLIF) 15.16.5. Others 15.17. Mexico Spine Biologics Market Forecast, by End-User 15.17.1. Hospitals 15.17.2. Ambulatory Surgical Centers 15.17.3. Others 15.18. Rest of South America Spine Biologics Market Forecast, by Product 15.18.1. Bone Allografts 15.18.1.1. Machined bone allograft 15.18.1.2. Demineralized bone matrix 15.18.2. Bone Graft Substitute 15.18.2.1. Synthetic Bone Grafts 15.18.2.2. Demineralized Bone Matrix (DBM) 15.18.2.3. Bone Morphogenetic Proteins (BMP) 15.18.3. Spinal Allografts 15.18.3.1. Machined Bones Allograft 15.18.3.2. Demineralized Bone Matrix 15.18.4. Platelet Rich Plasma 15.18.5. Cell-based Matrix 15.19. Rest of South America Spine Biologics Market Forecast, by Surgery Type 15.19.1. Anterior Cervical Discectomy and Fusion (ACDF) 15.19.2. Transforamenal Lumbar Interbody Fusion (TLIF) 15.19.3. Anterior Lumbar Interbody Fusion (ALIF) 15.19.4. Lateral Lumbar Interbody Fusion (LLIF) 15.19.5. Others 15.20. Rest of South America Spine Biologics Market Forecast, by End-User 15.20.1. Hospitals 15.20.2. Ambulatory Surgical Centers 15.20.3. Others 15.21. South America Spine Biologics Market Attractiveness Analysis 15.21.1. By Product 15.21.2. By Surgery Type 15.21.3. By End-User 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Medtronic Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. DePuy Synthes Companies 16.3.3. Zimmer Holding Inc. 16.3.4. Nuvasive Inc 16.3.5. Stryker Corporation 16.3.6. Orthofix International N.V. 16.3.7. Exactech Inc. 16.3.8. Wright Medical Technology 16.3.9. Alphatec Holdings 16.3.10. SeaSpine 16.3.11. Globus Medical 16.3.12. RTI Surgical 17. Primary Key Insights